433 related articles for article (PubMed ID: 11111232)
1. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
3. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
Weaver CH; Hazelton B; Birch R; Palmer P; Allen C; Schwartzberg L; West W
Blood; 1995 Nov; 86(10):3961-9. PubMed ID: 7579367
[TBL] [Abstract][Full Text] [Related]
4. Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
Villalón L; Odriozola J; Laraña JG; Zamora C; Pérez de Oteyza J; Jodra MH; López J; Herrera P; Roldán E; Ramos ML; Ramos P; Navarro JL
Hematol J; 2000; 1(6):374-81. PubMed ID: 11920217
[TBL] [Abstract][Full Text] [Related]
5. Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation.
Díaz MA; Villa M; Madero L; Benito A; Alegre A; Fernandez-Rañada JM
J Hematother; 1998 Aug; 7(4):367-73. PubMed ID: 9735868
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
8. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates.
MacVittie TJ; Farese AM; Davis TA; Lind LB; McKearn JP
Exp Hematol; 1999 Oct; 27(10):1557-68. PubMed ID: 10517498
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
10. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
[TBL] [Abstract][Full Text] [Related]
11. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.
Faucher C; Le Corroller AG; Chabannon C; Viens P; Stoppa AM; Bouabdallah R; Camerlo J; Vey N; Gravis G; Gastaut JA; Novakovitch G; Mannoni P; Bardou VJ; Moatti JP; Maraninchi D; Blaise D
J Hematother; 1996 Dec; 5(6):663-70. PubMed ID: 9117255
[TBL] [Abstract][Full Text] [Related]
13. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
14. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis.
Schots R; Van Riet I; Damiaens S; Flament J; Lacor P; Staelens Y; Steenssens L; van Camp B; De Waele M
Bone Marrow Transplant; 1996 Apr; 17(4):509-15. PubMed ID: 8722347
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
[TBL] [Abstract][Full Text] [Related]
16. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
18. Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics.
Diaz MA; Alegre A; Villa M; Granda A; de la Vega A; Ramirez M; Ruano D; Gonzalez A; Merino JM; Madero L
Bone Marrow Transplant; 1996 Oct; 18(4):699-703. PubMed ID: 8899183
[TBL] [Abstract][Full Text] [Related]
19. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
